Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline

Sionna Therapeutics found strong investor interest in its cystic fibrosis drugs, which could rival blockbuster Vertex Pharmaceuticals product Trikafta. The biotech has three internally developed programs that hit a target unaddressed by any currently available CF therapies. The post Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline appeared first on…

Read More

Links

Paths forward for accountable care.Value of continuity in primary care.CDC morale falling.What happened to big work comp PPOs?Homage to Khris Middleton: “They f—g did it.”

Read More